On October 16, a blood test called CIRRHOClear entered the Singapore market, offering a way to glimpse liver scarring before its symptoms announce themselves. Cirrhosis has long been a quiet erosion, often discovered only when the liver has already hardened past repair, and this test, born of a local biotechnology firm and the National Cancer Centre Singapore, tries to move that moment of recognition earlier. Its promise is modest but meaningful: a single ordinary sample, read for distress signals carried in small RNA molecules, that can guide a physician toward the people who most need attent
Singapore Blood Test CIRRHOClear Aims to Flag Liver Cirrhosis Risk Before Symptoms Appear
Cirrhosis causes an estimated 1.43 million deaths worldwide in 2021, and decompensated patients average about two years of life expectancy without transplant.
Decompensated cirrhosis averages about two years without a transplant
Mark
Why does a blood test for cirrhosis matter if doctors already have ultrasound and liver enzyme tests?
Mimi
Because those tools lack sensitivity for early scarring, according to Mirxes and NCCS. The accurate imaging methods exist, but they are mostly at specialist centres.
Mark
So the pitch is about getting detection into primary care.
Mimi
Yes. A standard blood draw at a clinic, with results sorted into high, intermediate or low risk, is meant to guide who needs further workup.
Luke
Worth noting the 89% and 95% figures come from clinical validation studies reported by the developers. The coverage doesn't say who ran them or how they were designed.
Mark
Is there anything to say how it performs in ordinary clinics?
Luke
Not yet. It launched on Oct 16, and real-world performance in primary care is unknown.
Mimi
The ELEGANCE study behind it followed 2,000 participants with liver disease over four years, which gives it a substantial base.
Luke
A base of people who already had liver disease, though. How it does in the broader group aged 40 and above isn't addressed.
Mark
And cost?
Luke
Not disclosed. That will shape whether it actually reaches the people it's meant for.
Mimi
The stakes are clear, though. Decompensated cirrhosis averages about two years of life without a transplant, so catching it earlier matters.
Le Pouls
- A silent disease has been hard to catch, because routine liver tests and ultrasound often miss early scarring until much damage is done.
- A new blood test, CIRRHOClear, launched in Singapore on October 16, sorting people into high, intermediate or low cirrhosis risk.
- Its developers are working to move detection out of specialist centres and into primary care clinics, where bottlenecks currently slow care.
- Reported accuracy of 89% for identifying risk and 95% for ruling it out has been encouraging, yet the price is still undisclosed.
- Plans to expand to other countries are underway, and doctors' willingness to adopt the test will determine whether it changes outcomes.
On October 16, a blood test called CIRRHOClear entered the Singapore market, offering a way to glimpse liver scarring before its symptoms announce themselves. Cirrhosis has long been a quiet erosion, often discovered only when the liver has already hardened past repair, and this test, born of a local biotechnology firm and the National Cancer Centre Singapore, tries to move that moment of recognition earlier. Its promise is modest but meaningful: a single ordinary sample, read for distress signals carried in small RNA molecules, that can guide a physician toward the people who most need attention. Whether it becomes a common instrument of primary care, rather than a specialist's refinement, remains a question the coming years will answer.
On October 16, a new blood test called CIRRHOClear reached the market in Singapore. Its purpose is to reveal who is at risk of liver cirrhosis before any symptoms appear, a gap that routine screening has struggled to close.
The test was developed by the local biotechnology firm Mirxes with the National Cancer Centre Singapore. It reads a combination of microRNAs from a standard blood sample. When the liver is damaged, these molecules enter the bloodstream as a kind of distress signal, and a proprietary algorithm sorts a person's risk into high, intermediate or low. It is intended for people aged 40 and above who already face higher risk, such as those with fatty liver disease, chronic hepatitis or alcohol-related liver conditions. In validation studies, it correctly identified cirrhosis risk in 89% of cases and ruled it out in 95%.
The stakes are high. Cirrhosis, the stage at which the liver becomes scarred and hardened and begins to fail, cannot be fully reversed, though early treatment can slow it. Once decompensated, patients live about two years on average without a transplant. Worldwide, the 2021 Global Burden of Disease study linked 1.43 million deaths to the condition that year, and unmanaged cirrhosis can progress to liver cancer. In Singapore, liver cancer is the third leading cause of cancer death in men.
Existing tools fall short for many patients. Enzyme tests and ultrasound lack sensitivity for early scarring, while more accurate imaging is concentrated in specialist centres. Liver biopsy is precise but invasive. CIRRHOClear draws on the four-year ELEGANCE study of 2,000 participants, and its backers hope it will let primary care doctors act sooner. The test will be offered at clinics and screening centres, with plans for other countries later. Its price has not yet been disclosed, and how widely doctors adopt it is still unknown.
On Oct 16, a blood test called CIRRHOClear went on the market in Singapore. It was built to do something routine screening has struggled with: show who is at risk of liver cirrhosis before any symptoms appear.
The test was developed by the local biotechnology firm Mirxes together with the National Cancer Centre Singapore (NCCS). It works from a standard blood sample and measures a combination of microRNAs, small RNA molecules involved in many essential biological processes. When the liver is damaged or inflamed, abnormal levels of particular microRNAs enter the bloodstream, which the developers describe as a distress signal. A proprietary algorithm reads those levels and sorts a person's cirrhosis risk into high, intermediate or low. The test is designed for people aged 40 and above.
The developers report results from clinical validation studies. The test correctly determined cirrhosis risk in 89% of cases and correctly identified people without the condition 95% of the time. It is meant for doctors to use with people already at higher risk, such as those with fatty liver disease, chronic hepatitis or alcohol-related liver conditions.
Cirrhosis is the stage at which the liver becomes shrunken, scarred and hardened, and its functions begin to fail. It follows chronic damage from causes that include fatty liver disease, heavy drinking and autoimmune liver disease. It cannot be fully reversed, but early detection and treatment can slow it and manage symptoms. For people with chronic hepatitis B or C, treatment can include antiviral drugs. Advanced disease carries a high risk of death: patients with decompensated cirrhosis, whose livers can no longer function normally, live about two years on average without a transplant.
The scale is large. The 2021 Global Burden of Disease study counted more than 1.7 billion cases of cirrhosis worldwide and 1.43 million deaths linked to it that year. Unmanaged, cirrhosis can progress to liver failure and to hepatocellular carcinoma, the most common form of primary liver cancer, which affects about 30 in every 100,000 people a year. In Singapore, liver cancer is the third leading cause of cancer death in men and the fifth most common in women.
Mirxes and NCCS say existing tools leave a gap, particularly in primary care. Routine liver enzyme blood tests and ultrasound lack the sensitivity to catch early scarring. Accurate imaging methods that measure tissue stiffness, such as transient elastography and magnetic resonance elastography, tend to be confined to specialist centres, which the two organisations say creates "significant care bottlenecks". Liver biopsy remains the gold standard, but it is invasive, with risks of pain and bleeding, and is unsuitable for routine population screening.
CIRRHOClear draws on findings from ELEGANCE, an NCCS-led study of 2,000 participants with liver disease. The four-year study aimed to produce clinical tools that identify people at risk of primary liver cancer earlier and more precisely. Pierce Chow, a senior consultant in surgery and surgical oncology at NCCS and Singapore General Hospital, and the study's principal investigator, said early detection is the best tool for changing the course of chronic liver conditions. He said the test gives physicians a practical way to stratify risk and make timely decisions.
Mirxes co-founder and chief executive Zhou Lihan pointed to the company's RNA platform, which he said has already shown early detection in stomach and lung cancers. He said he is confident CIRRHOClear will help primary care providers find liver scarring early, shifting care from reactive treatment toward prevention.
The test will be offered at clinics and screening centres, and Mirxes and NCCS plan to introduce it in other countries later. Its price was not immediately available, and how widely primary care doctors adopt it is yet to be seen.
Citations marquantes
Early detection is our best tool to alter the disease trajectory of chronic liver conditions.— Pierce Chow, senior consultant, NCCS and Singapore General Hospital
The test shifts liver care from reactive treatment to proactive prevention.— Zhou Lihan, co-founder and CEO, Mirxes (paraphrased)
Envie de l'histoire complète ?
Lire l'original sur The Straits Times ↗
Health & Medicine